64 related articles for article (PubMed ID: 15671249)
1. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells.
Steller MD; Shaw TJ; Vanderhyden BC; Ethier JF
Mol Cancer Res; 2005 Jan; 3(1):50-61. PubMed ID: 15671249
[TBL] [Abstract][Full Text] [Related]
2. KMT2D links TGF-β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity.
Lu S; Kim HS; Cao Y; Bedi K; Zhao L; Narayanan IV; Magnuson B; Gu Y; Yang J; Yi Z; Babaniamansour S; Shameon S; Xu C; Paulsen MT; Qiu P; Jeyarajan S; Ljungman M; Thomas D; Dou Y; Crawford H; di Magliano MP; Ge K; Yang B; Shi J
Int J Cancer; 2023 Aug; 153(3):552-570. PubMed ID: 37140208
[TBL] [Abstract][Full Text] [Related]
3. Evolving roles of activins and inhibins in ovarian cancer pathophysiology.
Evans ET; Horst B; Arend RC; Mythreye K
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C428-C437. PubMed ID: 36622068
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer-Associated Cachexia.
Korzun T; Moses AS; Kim J; Patel S; Schumann C; Levasseur PR; Diba P; Olson B; Rebola KGO; Norgard M; Park Y; Demessie AA; Eygeris Y; Grigoriev V; Sundaram S; Pejovic T; Brody JR; Taratula OR; Zhu X; Sahay G; Marks DL; Taratula O
Small; 2022 Nov; 18(44):e2204436. PubMed ID: 36098251
[TBL] [Abstract][Full Text] [Related]
5. A Review of Principal Studies on the Development and Treatment of Epithelial Ovarian Cancer in the Laying Hen
Pal P; Starkweather KN; Hales KH; Hales DB
Comp Med; 2021 Aug; 71(4):271-284. PubMed ID: 34325771
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
Tao JJ; Cangemi NA; Makker V; Cadoo KA; Liu JF; Rasco DW; Navarro WH; Haqq CM; Hyman DM
Clin Cancer Res; 2019 Sep; 25(18):5458-5465. PubMed ID: 31068369
[TBL] [Abstract][Full Text] [Related]
7. Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (Review).
Cui X; Shang S; Lv X; Zhao J; Qi Y; Liu Z
Mol Med Rep; 2019 Jun; 19(6):5053-5062. PubMed ID: 31059090
[TBL] [Abstract][Full Text] [Related]
8. ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells.
Portale F; Cricrì G; Bresolin S; Lupi M; Gaspari S; Silvestri D; Russo B; Marino N; Ubezio P; Pagni F; Vergani P; Kronnie GT; Valsecchi MG; Locatelli F; Rizzari C; Biondi A; Dander E; D'Amico G
Haematologica; 2019 Mar; 104(3):533-545. PubMed ID: 30262563
[TBL] [Abstract][Full Text] [Related]
9. Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma.
Zou G; Ren B; Liu Y; Fu Y; Chen P; Li X; Luo S; He J; Gao G; Zeng Z; Xiong W; Li G; Huang Y; Xu K; Zhang W
Cancer Sci; 2018 Nov; 109(11):3416-3427. PubMed ID: 30151927
[TBL] [Abstract][Full Text] [Related]
10. Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling.
Dean M; Davis DA; Burdette JE
Cancer Lett; 2017 Apr; 391():114-124. PubMed ID: 28115208
[TBL] [Abstract][Full Text] [Related]
11. Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.
Jenkins LM; Singh P; Varadaraj A; Lee NY; Shah S; Flores HV; O'Connell K; Mythreye K
J Biol Chem; 2016 Dec; 291(49):25716-25728. PubMed ID: 27784788
[TBL] [Abstract][Full Text] [Related]
12. Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion.
Loomans HA; Andl CD
Cancers (Basel); 2014 Dec; 7(1):70-91. PubMed ID: 25560921
[TBL] [Abstract][Full Text] [Related]
13. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.
Sioletic S; Czaplinski J; Hu L; Fletcher JA; Fletcher CD; Wagner AJ; Loda M; Demetri GD; Sicinska ET; Snyder EL
J Pathol; 2014 Oct; 234(2):190-202. PubMed ID: 24852265
[TBL] [Abstract][Full Text] [Related]
14. Genetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient mice.
Rajanahally S; Agno JE; Nalam RL; Weinstein MB; Loveland KL; Matzuk MM; Li Q
Reprod Biol Endocrinol; 2010 Jun; 8():69. PubMed ID: 20565978
[TBL] [Abstract][Full Text] [Related]
15. Roles for the type III TGF-beta receptor in human cancer.
Gatza CE; Oh SY; Blobe GC
Cell Signal; 2010 Aug; 22(8):1163-74. PubMed ID: 20153821
[TBL] [Abstract][Full Text] [Related]
16. Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors.
Middlebrook BS; Eldin K; Li X; Shivasankaran S; Pangas SA
Endocrinology; 2009 Dec; 150(12):5208-17. PubMed ID: 19819941
[TBL] [Abstract][Full Text] [Related]
17. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.
Bilandzic M; Chu S; Farnworth PG; Harrison C; Nicholls P; Wang Y; Escalona RM; Fuller PJ; Findlay JK; Stenvers KL
Mol Endocrinol; 2009 Apr; 23(4):539-48. PubMed ID: 19164448
[TBL] [Abstract][Full Text] [Related]
18. The role of activin A and Akt/GSK signaling in ovarian tumor biology.
Do TV; Kubba LA; Antenos M; Rademaker AW; Sturgis CD; Woodruff TK
Endocrinology; 2008 Aug; 149(8):3809-16. PubMed ID: 18450971
[TBL] [Abstract][Full Text] [Related]
19. Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion.
Chen CL; Cheung LW; Lau MT; Choi JH; Auersperg N; Wang HS; Wong AS; Leung PC
Endocrine; 2007 Jun; 31(3):311-20. PubMed ID: 17906381
[TBL] [Abstract][Full Text] [Related]
20. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.
Jung BH; Beck SE; Cabral J; Chau E; Cabrera BL; Fiorino A; Smith EJ; Bocanegra M; Carethers JM
Gastroenterology; 2007 Feb; 132(2):633-44. PubMed ID: 17258738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
